Every material Form 8-K CELESTICA INC has filed with the SEC since October 26, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Celestica said the Toronto Stock Exchange accepted its normal course issuer bid to repurchase up to 3,132,127 common shares, about 2.5% of its public float, over the next 12 months. Purchases are set to begin November 3, 2026 and end by November 2, 2027, and will be funded from existing cash and its credit facility or other available debt, with repurchased shares cancelled. For shareholders, the bid is a potential use of capital that could reduce the share count, though the company has not committed to buying the full amount.
Up to 3,132,127 common shares, about 2.5% of the public float as of October 20, 2026
Purchases scheduled to run from November 3, 2026 to the earlier of November 2, 2027 or completion of the bid
Daily TSX purchases limited to 109,076 shares, based on average daily volume for the six months ended September 30, 2026
Prior bid expires November 2, 2026; the company had repurchased and cancelled 205,184 shares at a weighted average price of US$271.75
Celestica furnished an Investor and Analyst Day presentation as Exhibit 99.1 to this 8-K, to be used with a conference call on October 27, 2026 about its results for the quarter ended September 30, 2026. The presentation shows full-year 2025 revenue rose to $12.4 billion from $9.6 billion in 2024, and diluted earnings per share rose to $7.16 from $3.61.
FY 2025 revenue was $12,390.9 million, up from $9,646.0 million in FY 2024.
FY 2025 GAAP net earnings were $832.5 million, compared with $428.0 million in FY 2024.
FY 2025 diluted EPS was $7.16, compared with $3.61 in FY 2024; non-GAAP adjusted diluted EPS was $6.05.
The conference call on October 27, 2026 covers Q3 2026 results and the Investor and Analyst Day.
Celestica reported third-quarter 2026 revenue of $5.83 billion, up 83% from a year earlier, and adjusted EPS of $3.30, above its $2.88 to $3.08 guidance range. It raised its 2026 revenue outlook to $21.0 billion and adjusted EPS outlook to $11.55, and gave a first 2027 outlook of $40.0 billion in revenue and $21.50 adjusted EPS, which matters to shareholders because it signals higher expected earnings. The company cut its 2026 free cash flow outlook to $460 million from $600 million, citing working capital investments.
Q3 2026 adjusted EPS was $3.30 and GAAP EPS was $3.26, compared with $1.58 and $2.31 in Q3 2025.
2026 outlook raised: revenue of $21.0 billion (previously $20.5 billion) and adjusted EPS of $11.55 (previously $11.30).
2026 free cash flow outlook lowered to $460 million from $600 million, primarily due to working capital investments to support 2027 growth.
2027 outlook: revenue of $40.0 billion and adjusted EPS of $21.50; a new normal course issuer bid is planned for Q4 2026 after the current one expires November 2, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CELESTICA INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →